AU2623795A - Immunogenic pharmaceuticals - Google Patents

Immunogenic pharmaceuticals

Info

Publication number
AU2623795A
AU2623795A AU26237/95A AU2623795A AU2623795A AU 2623795 A AU2623795 A AU 2623795A AU 26237/95 A AU26237/95 A AU 26237/95A AU 2623795 A AU2623795 A AU 2623795A AU 2623795 A AU2623795 A AU 2623795A
Authority
AU
Australia
Prior art keywords
immunogenic
pharmaceuticals
immunogenic pharmaceuticals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU26237/95A
Inventor
Alain Robert Michael Townsend
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
CHANCELLOR MASTERS
University of Oxford
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHANCELLOR MASTERS, University of Oxford, Medical Research Council filed Critical CHANCELLOR MASTERS
Publication of AU2623795A publication Critical patent/AU2623795A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU26237/95A 1994-06-01 1995-06-01 Immunogenic pharmaceuticals Abandoned AU2623795A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9410922A GB9410922D0 (en) 1994-06-01 1994-06-01 Vaccines
GB9410922 1994-06-01
PCT/GB1995/001274 WO1995032731A2 (en) 1994-06-01 1995-06-01 Immunogenic pharmaceuticals

Publications (1)

Publication Number Publication Date
AU2623795A true AU2623795A (en) 1995-12-21

Family

ID=10755982

Family Applications (1)

Application Number Title Priority Date Filing Date
AU26237/95A Abandoned AU2623795A (en) 1994-06-01 1995-06-01 Immunogenic pharmaceuticals

Country Status (5)

Country Link
EP (1) EP0762891A1 (en)
JP (1) JPH10504702A (en)
AU (1) AU2623795A (en)
GB (1) GB9410922D0 (en)
WO (1) WO1995032731A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958684A (en) * 1995-10-02 1999-09-28 Van Leeuwen; Frederik Willem Diagnosis of neurodegenerative disease
WO1998045322A2 (en) * 1997-04-10 1998-10-15 Royal Netherlands Academy Of Arts And Sciences Diagnosis method and reagents
NO314086B1 (en) * 1998-05-08 2003-01-27 Gemvax As Peptides and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids and virus vectors encompassing such DNA sequences and their use for the preparation of pharmaceutical preparations for
NO315238B1 (en) 1998-05-08 2003-08-04 Gemvax As Peptides derived from reading frame shift mutations in the TBF <beta> II or BAX gene, and pharmaceutical compositions containing them, nucleic acid sequences encoding such peptides, plasmids, and virus vector-encompassing such nucleic acid
ITMI20030434A1 (en) * 2003-03-07 2004-09-08 Istituto Oncologico Romagnolo Coope Rativa Sociale METHOD FOR THE DETECTION OF COLON-RECTUM TUMORS.
EP1994181A4 (en) * 2006-02-27 2010-05-19 Univ Arizona Identification and use of novopeptides for the treatment of cancer
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
EP3075389A1 (en) * 2015-03-31 2016-10-05 Technische Universität München T cell receptors and peptides derived by mutations for the treatment of cancer
CN108495649A (en) 2016-01-08 2018-09-04 瓦西博迪公司 The new epiposition vaccine of therapeutic anti-cancer
EP3630130B1 (en) 2017-06-02 2022-08-31 Arizona Board of Regents on behalf of Arizona State University A method to create personalized cancer vaccines
GB201710812D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
WO2020022903A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
EP3827262A1 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
WO2020022900A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
US12005104B2 (en) 2018-07-26 2024-06-11 Curevac Netherlands B.V. Cancer vaccines for colorectal cancer
EP3826669A2 (en) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Off-the-shelf cancer vaccines
CA3106570A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Cancer vaccines for uterine cancer
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687737A (en) * 1982-11-12 1987-08-18 Massachusetts Institute Of Technology Mammalian suppressor genes
EP0565794A1 (en) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induction of CTL responses
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells

Also Published As

Publication number Publication date
WO1995032731A2 (en) 1995-12-07
GB9410922D0 (en) 1994-07-20
JPH10504702A (en) 1998-05-12
EP0762891A1 (en) 1997-03-19
WO1995032731A3 (en) 1995-12-21

Similar Documents

Publication Publication Date Title
AU3532195A (en) Medicaments
AU3304795A (en) Bisresorcinyltriazines
AU2832295A (en) Cytoanalyzer
AU3304995A (en) 2-Hydroxyphenyltriazines
AU2623795A (en) Immunogenic pharmaceuticals
AU2837895A (en) Thiazine- or thiazepine-derivatives
AU4131596A (en) Polyglycomers
AU4044795A (en) Handleset
AU2308295A (en) Heterocyclylbenzonitriles
AU1963395A (en) Boom-structure
AU4029295A (en) Thienopyridones
AU1475595A (en) Pharmaceutical preparation
AU3991695A (en) Ranging system
AU7469594A (en) Poop-scoop
AU3166195A (en) Acylimidazopyridines
AU4590996A (en) Boekomslag
AUPM365494A0 (en) Pre-chiller
AU2411395A (en) Hydrocopter
AU3166095A (en) Benzylimidazopyridines
AU6409894A (en) Recognin vaccines
AU1603595A (en) Meso-azanoradamantanes
AU3446995A (en) Biodestumping
AU3417395A (en) Hydro-ethano-indeno-pyridines
AUPM374794A0 (en) Compartmentalizer
AU658811B3 (en) Bum-bag